Abstract Body

Background: Immune response to standard hepatitis B (HBV) vaccination is decreased in HIV-infected patients, and it has been recently shown that a double dose HBV primary vaccination regimen improved serological response. However, the immunogenicity of this regimen in non responders to a previous vaccination is unknown.

Methods: In an open-label, multicenter, 1:1 parallel groups randomized clinical trial, stratified according to CD4 cell count (200-349, and > 350 cells/μl), 411 HIV-infected adults, CD4 T cells ≥ 200/μl, and previously vaccinated against HBV, without HBV markers, received a booster dose (20 μg) of HBV vaccine. 178 of them who did not respond to the boost were randomized to receive HBV vaccination with either 3 intramuscular (IM) standard doses (20 μg, group A, n=90), or 3 IM double doses (40 μg, group B, n=88) at weeks 0, 4 and 24. Subjects with anti-HBs ≥ 10 mUI/mL and ≥ 100 mUI/mL at week 28 were defined as responders (main endpoint) and high responders, respectively.

Results: The median age of the population was 44 years (IQR 40-51); 78% were male; the median CD4 cell count was 512 cells/μl (IQR 424-682); 71% had plasma viral load < 50 copies/ml. In an intent-to-treat analysis (missing = failures), the percentage of responders and high responders were 67% and 26% in group A, 74% and 47% in group B (P=.33 and P=.002). At week 28, the geometric mean titre of anti-HBs were 20 and 60 mUI/mL in group A and B respectively (P=.0004). BMI was the only factor associated with response to vaccination (>=25 vs <25, odds-ratio=2.42; 95%CI (1.1-5.3) P=.028). Among responders at week 28, 43% and 64% in group A and B respectively, had anti-HBs ≥ 10 mUI/mL at week 72 (p=.0069), and geometric mean titre of anti-HBs were 11 and 35 mUI/mL (p=.0016) in group A and B at week 72. There were two serious adverse events associated with the vaccine (1 in each group): exacerbation of psoriasis and severe headaches. Local reactions occurred in 5% of patients in group A versus 15% in group B (P=.02).

Conclusions: In HIV-1 infected adults who did not respond to a standard dose HBV vaccination, a double-dose re-vaccination regimen does not increase the response rate but provides higher level of anti-HBs titre, with longer durability, compared with a standard re-vaccination regimen.